Adaptive licensing: creating a safe haven for discussions
This article was originally published in SRA
The concept of adaptive licensing as a means of making innovative medicines available faster is generating much excitement, but some drug companies are worried about how this emerging approach might be implemented. Lynn Baird and Gigi Hirsch say their concerns can be overcome.
You may also be interested in...
A rare disclosure by China’s national health insurance payer shows how a major state-owned drug maker used its market-dominating position to dodge price-lowering schemes and increase drug prices more than 10-fold.
What are the special regulatory pathways that allow the use of unapproved devices? Asia Regulatory Professionals Association’s Rachel Lee and Helena Baric supply the answer, with reference to the systems used in the US and Singapore.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.